Looking ahead to 2030, our model projects NET could trade at an average price of $303.52, with a potential range between $227.64 and $379.40. This represents a potential 35.8% return from today's ...

Previous research has demonstrated that the introduction of a new brand-name pharmaceutical competitor does not lower list prices for existing competitive therapies. However, no study has ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

Policy decisions benefit from having more rather than less information, so requiring data on actual net costs will improve negotiations over the “maximum fair price” for select drugs under Medicare.

Medicare has completed its second round of price negotiations for 15 top-selling prescription drugs and posted maximum fair prices, per an Inflation Reduction Act provision. The announced net prices, ...